JP6688551B2 - 三重特異性結合タンパク質と使用方法 - Google Patents
三重特異性結合タンパク質と使用方法 Download PDFInfo
- Publication number
- JP6688551B2 JP6688551B2 JP2018512836A JP2018512836A JP6688551B2 JP 6688551 B2 JP6688551 B2 JP 6688551B2 JP 2018512836 A JP2018512836 A JP 2018512836A JP 2018512836 A JP2018512836 A JP 2018512836A JP 6688551 B2 JP6688551 B2 JP 6688551B2
- Authority
- JP
- Japan
- Prior art keywords
- domain
- antigen binding
- trispecific
- binding protein
- trispecific antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108091008324 binding proteins Proteins 0.000 title claims description 4
- 238000000034 method Methods 0.000 title description 29
- 102000014914 Carrier Proteins Human genes 0.000 title description 4
- 102000025171 antigen binding proteins Human genes 0.000 claims description 166
- 108091000831 antigen binding proteins Proteins 0.000 claims description 166
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 84
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 84
- 239000000427 antigen Substances 0.000 claims description 72
- 108091007433 antigens Proteins 0.000 claims description 72
- 102000036639 antigens Human genes 0.000 claims description 72
- 241000282414 Homo sapiens Species 0.000 claims description 67
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 39
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 38
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 38
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 18
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 18
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 18
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 15
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 15
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 10
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 9
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 9
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- JARGNLJYKBUKSJ-KGZKBUQUSA-N (2r)-2-amino-5-[[(2r)-1-(carboxymethylamino)-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;hydrobromide Chemical compound Br.OC(=O)[C@H](N)CCC(=O)N[C@H](CO)C(=O)NCC(O)=O JARGNLJYKBUKSJ-KGZKBUQUSA-N 0.000 claims description 4
- 108010044804 gamma-glutamyl-seryl-glycine Proteins 0.000 claims description 4
- 101000642536 Apis mellifera Venom serine protease 34 Proteins 0.000 claims description 3
- 101100372806 Caenorhabditis elegans vit-3 gene Proteins 0.000 claims description 3
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 claims description 3
- 101000633445 Homo sapiens Structural maintenance of chromosomes protein 2 Proteins 0.000 claims description 3
- 102100025096 Mesothelin Human genes 0.000 claims description 3
- 102100029540 Structural maintenance of chromosomes protein 2 Human genes 0.000 claims description 3
- 230000009260 cross reactivity Effects 0.000 claims description 3
- 229960003816 muromonab-cd3 Drugs 0.000 claims description 3
- 229950002610 otelixizumab Drugs 0.000 claims description 3
- 229950004393 visilizumab Drugs 0.000 claims description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 102000023732 binding proteins Human genes 0.000 claims 1
- 230000027455 binding Effects 0.000 description 134
- 210000004027 cell Anatomy 0.000 description 90
- 108090000623 proteins and genes Proteins 0.000 description 67
- 102000004169 proteins and genes Human genes 0.000 description 63
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 57
- 235000018102 proteins Nutrition 0.000 description 55
- 201000010099 disease Diseases 0.000 description 40
- 210000001744 T-lymphocyte Anatomy 0.000 description 35
- 108090000765 processed proteins & peptides Proteins 0.000 description 32
- 238000003556 assay Methods 0.000 description 21
- 102000009027 Albumins Human genes 0.000 description 19
- 108010088751 Albumins Proteins 0.000 description 19
- 102000004196 processed proteins & peptides Human genes 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 19
- 210000004881 tumor cell Anatomy 0.000 description 18
- 238000003379 elimination reaction Methods 0.000 description 17
- 208000035475 disorder Diseases 0.000 description 16
- 230000008030 elimination Effects 0.000 description 16
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 15
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 108091033319 polynucleotide Proteins 0.000 description 15
- 102000040430 polynucleotide Human genes 0.000 description 15
- 239000002157 polynucleotide Substances 0.000 description 15
- 150000003384 small molecules Chemical class 0.000 description 15
- 229920001184 polypeptide Polymers 0.000 description 14
- 230000008685 targeting Effects 0.000 description 14
- 239000013598 vector Substances 0.000 description 13
- 238000009826 distribution Methods 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 11
- 125000000539 amino acid group Chemical group 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 239000011230 binding agent Substances 0.000 description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 238000009792 diffusion process Methods 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 7
- 230000035515 penetration Effects 0.000 description 7
- 108010025905 Cystine-Knot Miniproteins Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000022534 cell killing Effects 0.000 description 6
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 231100000682 maximum tolerated dose Toxicity 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 241000282567 Macaca fascicularis Species 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000002784 cytotoxicity assay Methods 0.000 description 4
- 231100000263 cytotoxicity test Toxicity 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 108010082117 matrigel Proteins 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000001542 size-exclusion chromatography Methods 0.000 description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000003950 B-cell lymphoma Diseases 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 238000012575 bio-layer interferometry Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 208000026278 immune system disease Diseases 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000001613 neoplastic effect Effects 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 230000005730 ADP ribosylation Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000282836 Camelus dromedarius Species 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 239000012505 Superdex™ Substances 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003302 anti-idiotype Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000000375 direct analysis in real time Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000012063 dual-affinity re-targeting Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000006251 gamma-carboxylation Effects 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000033444 hydroxylation Effects 0.000 description 2
- 238000005805 hydroxylation reaction Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000010232 migration assay Methods 0.000 description 2
- 230000009149 molecular binding Effects 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- -1 or X35-3 Proteins 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 108020001580 protein domains Proteins 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000019635 sulfation Effects 0.000 description 2
- 238000005670 sulfation reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LFEGKCKGGNXWDV-KBPBESRZSA-N (2s)-2-[[(1s)-1-carboxy-5-[(4-iodophenyl)carbamoylamino]pentyl]carbamoylamino]pentanedioic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)N[C@H](C(O)=O)CCCCNC(=O)NC1=CC=C(I)C=C1 LFEGKCKGGNXWDV-KBPBESRZSA-N 0.000 description 1
- OXUUJYOSVPMNKP-GJZGRUSLSA-N (2s)-2-[[(1s)-1-carboxy-5-[(4-iodophenyl)methylamino]pentyl]carbamoylamino]pentanedioic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)N[C@H](C(O)=O)CCCCNCC1=CC=C(I)C=C1 OXUUJYOSVPMNKP-GJZGRUSLSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 238000012815 AlphaLISA Methods 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical class C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010017707 Fibronectin Receptors Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 101100356020 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) recA gene Proteins 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100495232 Homo sapiens MS4A1 gene Proteins 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100042680 Mus musculus Slc7a1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000010516 arginylation Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000013357 binding ELISA Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000013377 clone selection method Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000050 cytotoxic potential Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000002211 flavins Chemical class 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 229910003472 fullerene Inorganic materials 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000014828 interferon-gamma production Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 239000002073 nanorod Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229950000037 pasotuxizumab Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000010572 single replacement reaction Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 238000011311 validation assay Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020066802A JP6906653B2 (ja) | 2015-05-21 | 2020-04-02 | 三重特異性結合タンパク質と使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562165153P | 2015-05-21 | 2015-05-21 | |
| US62/165,153 | 2015-05-21 | ||
| US201562165833P | 2015-05-22 | 2015-05-22 | |
| US62/165,833 | 2015-05-22 | ||
| US201662305088P | 2016-03-08 | 2016-03-08 | |
| US62/305,088 | 2016-03-08 | ||
| PCT/US2016/033644 WO2016187594A1 (en) | 2015-05-21 | 2016-05-20 | Trispecific binding proteins and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020066802A Division JP6906653B2 (ja) | 2015-05-21 | 2020-04-02 | 三重特異性結合タンパク質と使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018517431A JP2018517431A (ja) | 2018-07-05 |
| JP2018517431A5 JP2018517431A5 (enExample) | 2019-06-20 |
| JP6688551B2 true JP6688551B2 (ja) | 2020-04-28 |
Family
ID=57320980
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018512836A Active JP6688551B2 (ja) | 2015-05-21 | 2016-05-20 | 三重特異性結合タンパク質と使用方法 |
| JP2020066802A Active JP6906653B2 (ja) | 2015-05-21 | 2020-04-02 | 三重特異性結合タンパク質と使用方法 |
| JP2021106877A Active JP7411316B2 (ja) | 2015-05-21 | 2021-06-28 | 三重特異性結合タンパク質と使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020066802A Active JP6906653B2 (ja) | 2015-05-21 | 2020-04-02 | 三重特異性結合タンパク質と使用方法 |
| JP2021106877A Active JP7411316B2 (ja) | 2015-05-21 | 2021-06-28 | 三重特異性結合タンパク質と使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US9708412B2 (enExample) |
| EP (2) | EP3297672B1 (enExample) |
| JP (3) | JP6688551B2 (enExample) |
| KR (2) | KR20190080992A (enExample) |
| CN (2) | CN111234027A (enExample) |
| AU (3) | AU2016263808B2 (enExample) |
| BR (1) | BR112017024899A2 (enExample) |
| CA (1) | CA2986575A1 (enExample) |
| EA (1) | EA201792573A1 (enExample) |
| ES (1) | ES2889906T3 (enExample) |
| IL (3) | IL274151B (enExample) |
| MX (2) | MX383614B (enExample) |
| SG (1) | SG10202002131PA (enExample) |
| WO (1) | WO2016187594A1 (enExample) |
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016263808B2 (en) | 2015-05-21 | 2019-01-03 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| WO2017165681A1 (en) | 2016-03-24 | 2017-09-28 | Gensun Biopharma Inc. | Trispecific inhibitors for cancer treatment |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| MX2018014227A (es) | 2016-05-20 | 2019-08-22 | Harpoon Therapeutics Inc | Proteinas de union de cadena unica de fragmento variable cd3. |
| MX2018014228A (es) | 2016-05-20 | 2019-08-12 | Harpoon Therapeutics Inc | Proteina de union de albumina sérica de dominio unico. |
| WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
| AU2017363300A1 (en) * | 2016-11-23 | 2019-06-20 | Harpoon Therapeutics, Inc. | Prostate specific membrane antigen binding protein |
| WO2018098356A1 (en) * | 2016-11-23 | 2018-05-31 | Harpoon Therapeutics, Inc. | Psma targeting trispecific proteins and methods of use |
| US10537637B2 (en) | 2017-01-05 | 2020-01-21 | Gensun Biopharma Inc. | Checkpoint regulator antagonists |
| US12473343B2 (en) | 2017-01-10 | 2025-11-18 | The General Hospital Corporation | Targeted t cells with cytotoxicity toward immunosuppressive cells |
| WO2018136725A1 (en) * | 2017-01-19 | 2018-07-26 | Harpoon Therapeutics, Inc. | Innate immune cell inducible binding proteins and methods of use |
| US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| WO2018160671A1 (en) * | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Targeted checkpoint inhibitors and methods of use |
| TWI676681B (zh) * | 2017-03-29 | 2019-11-11 | 臺北醫學大學 | 具抗原專一性的t細胞及其用途 |
| CN110520524A (zh) * | 2017-04-14 | 2019-11-29 | 综合医院公司 | 靶向肿瘤微环境的嵌合抗原受体t细胞 |
| US20200270362A1 (en) * | 2017-05-12 | 2020-08-27 | Harpoon Therapeutics, Inc. | Msln targeting trispecific proteins and methods of use |
| IL300964A (en) | 2017-05-12 | 2023-04-01 | Harpoon Therapeutics Inc | mesothelin binding proteins |
| KR20200026810A (ko) * | 2017-05-12 | 2020-03-11 | 하푼 테라퓨틱스, 인크. | Msln 표적화 삼중 특이적 단백질 및 사용 방법 |
| US12098203B2 (en) * | 2017-06-05 | 2024-09-24 | Numab Therapeutics AG | Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA |
| AU2018328291B2 (en) | 2017-09-08 | 2022-10-27 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| WO2019051122A2 (en) * | 2017-09-08 | 2019-03-14 | Maverick Therapeutics, Inc. | CONDITIONAL ACTIVATED BOND FRACTIONS CONTAINING FC REGIONS |
| FI3694529T3 (fi) * | 2017-10-13 | 2024-09-17 | Harpoon Therapeutics Inc | Trispesifiset proteiinit ja niiden käyttömenetelmät |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| CN109970860A (zh) * | 2017-12-27 | 2019-07-05 | 信达生物制药(苏州)有限公司 | 三链抗体、其制备方法及其用途 |
| JP7369127B2 (ja) | 2017-12-28 | 2023-10-25 | ナンジン レジェンド バイオテック カンパニー，リミテッド | Ｔｉｇｉｔに対する単一ドメイン抗体及びその変異体 |
| CA3085864A1 (en) * | 2018-01-08 | 2019-07-11 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| TWI802633B (zh) | 2018-01-15 | 2023-05-21 | 大陸商南京傳奇生物科技有限公司 | 針對pd-1之單域抗體及其變異體 |
| JP2021515806A (ja) | 2018-03-02 | 2021-06-24 | シーディアール−ライフ・アクチェンゲゼルシャフトＣｄｒ−Ｌｉｆｅ Ａｇ | 三重特異性抗原結合タンパク質 |
| WO2019175250A1 (en) | 2018-03-13 | 2019-09-19 | Smivet B.V. | Single domain antibodies binding to tetanus neurotoxin |
| MX2020012217A (es) | 2018-05-14 | 2021-03-02 | Harpoon Therapeutics Inc | Porción de unión para activación condicional de moléculas de inmunoglobulina. |
| CA3100007A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| MX2020012248A (es) | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de citocina activables y metodos de uso de los mismos. |
| CA3102562A1 (en) | 2018-06-07 | 2019-12-12 | Cullinan Management, Inc. | Multi-specific binding proteins and methods of use thereof |
| WO2019246003A1 (en) * | 2018-06-18 | 2019-12-26 | Anwita Biosciences, Inc. | Anti-mesothelin constructs and uses thereof |
| US10647773B2 (en) | 2018-06-29 | 2020-05-12 | Gensun Biopharma, Inc. | Trispecific antagonists |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| CN113286817B (zh) * | 2018-09-25 | 2025-01-28 | 哈普恩治疗公司 | Dll3结合蛋白及使用方法 |
| TWI821474B (zh) | 2018-12-07 | 2023-11-11 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｃｄ３抗體及其藥物用途 |
| CN113508134B (zh) * | 2019-02-22 | 2024-12-03 | 安维达生物科技公司 | 白蛋白结合抗体及其用途 |
| JP2022524338A (ja) | 2019-03-05 | 2022-05-02 | 武田薬品工業株式会社 | 拘束され、条件的に活性化された結合タンパク質 |
| AU2019439345B2 (en) * | 2019-03-29 | 2024-08-08 | Green Cross Corporation | Fusion protein comprising anti-mesothelin antibody, anti-CD3 antibody or anti-EGFR antibody, bispecific or trispecific antibody comprising same, and uses thereof |
| PE20220142A1 (es) | 2019-04-05 | 2022-01-27 | Teneobio Inc | Anticuerpos de cadena pesada que se unen al psma |
| KR20220023988A (ko) | 2019-05-14 | 2022-03-03 | 웨어울프 세라퓨틱스, 인크. | 분리 모이어티 및 이의 사용 방법 |
| AU2020275002A1 (en) * | 2019-05-14 | 2021-12-23 | Harpoon Therapeutics, Inc. | EpCAM binding proteins and methods of use |
| BR112021022682A2 (pt) | 2019-05-14 | 2022-02-22 | Provention Bio Inc | Métodos e composições para prevenir diabetes do tipo 1 |
| UY38701A (es) | 2019-05-21 | 2020-12-31 | Novartis Ag | Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas |
| CN114340735B (zh) | 2019-06-28 | 2024-11-12 | 璟尚生物制药公司 | 突变的TGFβ1-RII胞外域和免疫球蛋白支架组成的抗肿瘤拮抗剂 |
| WO2021004400A1 (zh) * | 2019-07-06 | 2021-01-14 | 苏州克睿基因生物科技有限公司 | 一种表达cd3抗体受体复合物的免疫细胞及其用途 |
| US20220403035A1 (en) * | 2019-11-06 | 2022-12-22 | Amgen Research ( Munich) Gmbh | Multitargeting antigen-binding molecules for use in proliferative diseases |
| EP4058471A1 (en) | 2019-11-14 | 2022-09-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| IL293780A (en) * | 2019-12-11 | 2022-08-01 | Cullinan Man Inc | Anti-serum albumin antibodies |
| JP7780434B2 (ja) | 2019-12-11 | 2025-12-04 | カリナン セラピューティクス インコーポレイテッド | 抗ｃｄ１９抗体および多重特異性結合タンパク質 |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| WO2021163364A1 (en) * | 2020-02-12 | 2021-08-19 | Abbvie Biotechnology Ltd. | Trispecific binding molecules |
| AU2021224851A1 (en) | 2020-02-21 | 2022-09-15 | Harpoon Therapeutics, Inc. | FLT3 binding proteins and methods of use |
| CA3218661A1 (en) | 2020-04-04 | 2022-11-17 | David Campbell | Compositions and methods related to tumor activated antibodies targeting egfr and effector cell antigens |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| TWI806088B (zh) * | 2020-06-30 | 2023-06-21 | 大陸商和鉑醫藥（上海）有限責任公司 | 具有H2L2與HCAb結構的結合蛋白 |
| WO2022006562A1 (en) | 2020-07-03 | 2022-01-06 | Dana-Farber Cancer Institute, Inc. | Multispecific coronavirus antibodies |
| CA3188601A1 (en) | 2020-07-08 | 2022-01-13 | LAVA Therapeutics N.V. | Antibodies that bind psma and gamma-delta t cell receptors |
| WO2022032023A2 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il23r binding molecules and methods of use |
| CA3190430A1 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il10rb binding molecules and methods of use |
| AU2021320233A1 (en) | 2020-08-05 | 2023-03-23 | Synthekine, Inc. | IL10Ra binding molecules and methods of use |
| US12448457B2 (en) | 2020-08-05 | 2025-10-21 | Synthekine, Inc. | GP130 binding molecules and methods of use |
| US12018085B2 (en) | 2020-08-05 | 2024-06-25 | Synthekine, Inc. | Interferon-gamma R2 (IFNGR2) binding molecules comprising single-domain antibodies and method of use thereof to treat autoimmune and inflammatory diseases |
| JP7652883B2 (ja) | 2020-08-05 | 2025-03-27 | シンセカイン インコーポレイテッド | ＩＬ２７Ｒα結合分子および使用方法 |
| KR102773428B1 (ko) | 2020-08-05 | 2025-02-28 | 신테카인, 인크. | Il10 수용체 결합 분자 및 사용 방법 |
| EP4192502A4 (en) | 2020-08-05 | 2024-10-09 | Synthekine, Inc. | Compositions and methods related to il27 receptor binding |
| US11859001B2 (en) | 2020-08-05 | 2024-01-02 | Synthekine, Inc. | IL12RB1-Binding molecules and methods of use |
| EP4192863A4 (en) | 2020-08-05 | 2025-07-30 | Synthekine Inc | IL2RG BINDING MOLECULES AND METHODS OF USE |
| WO2022032042A1 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il12 receptor synthetic cytokines and methods of use |
| US12234291B2 (en) | 2020-08-05 | 2025-02-25 | Synthekine, Inc. | IL2RB binding molecules and methods of use |
| US12122839B2 (en) | 2020-08-05 | 2024-10-22 | Synthekine, Inc. | IFNGR binding synthetic cytokines and methods of use |
| EP4259193A4 (en) | 2020-12-09 | 2025-01-15 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| EP4274616A2 (en) * | 2021-01-11 | 2023-11-15 | Synthekine, Inc. | Compositions and methods related to receptor pairing |
| JP2024510098A (ja) * | 2021-02-19 | 2024-03-06 | イノベント バイオロジクス（スーチョウ）カンパニー，リミティド | 抗ＧＰＲＣ５ＤｘＢＣＭＡｘＣＤ３三重特異性抗体およびその使用 |
| WO2022212732A1 (en) * | 2021-04-01 | 2022-10-06 | Harpoon Therapeutics, Inc. | Psma targeting tritacs and methods of use |
| EP4334354A1 (en) | 2021-05-06 | 2024-03-13 | Dana-Farber Cancer Institute, Inc. | Antibodies against alk and methods of use thereof |
| JP2024523033A (ja) | 2021-06-17 | 2024-06-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規の三重特異的結合分子 |
| EP4395812A1 (en) | 2021-08-31 | 2024-07-10 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treatment of autoimmune disorders and cancer |
| KR20240123846A (ko) | 2021-11-24 | 2024-08-14 | 다나-파버 캔서 인스티튜트 인크. | Ctla-4에 대한 항체 및 이의 사용 방법 |
| WO2023114544A1 (en) | 2021-12-17 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Antibodies and uses thereof |
| US20250051755A1 (en) | 2021-12-17 | 2025-02-13 | Dana-Farber Cancer Institute, Inc. | Platform for antibody discovery |
| WO2023134742A1 (zh) * | 2022-01-14 | 2023-07-20 | 浙江道尔生物科技有限公司 | 一种三靶点抗肿瘤药物、其制备方法及其应用 |
| CN119562969A (zh) * | 2022-02-07 | 2025-03-04 | 托瑞多治疗公司 | 多特异性结合蛋白质组合物及其用途 |
| CN114621349B (zh) * | 2022-02-09 | 2023-12-01 | 青岛大学附属医院 | 靶向pd-l1/hsa/ccl5三特异性纳米抗体及其衍生物和应用 |
| AU2023249274A1 (en) * | 2022-04-07 | 2024-10-24 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
| WO2024039672A2 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against msln and methods of use thereof |
| CA3263665A1 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Anti-CLDN4 antibodies and their methods of use |
| WO2025024674A2 (en) * | 2023-07-26 | 2025-01-30 | Promab Biotechnologies, Inc. | Method for treating local and distant tumors |
| WO2025214418A1 (en) * | 2024-04-09 | 2025-10-16 | Abogen Life Sciences (Shanghai) Co., Ltd. | Agents that bind to cd3 and cd19, nucleic acids encoding the same and uses thereof |
Family Cites Families (433)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6303121B1 (en) | 1992-07-30 | 2001-10-16 | Advanced Research And Technology | Method of using human receptor protein 4-1BB |
| US6355476B1 (en) | 1988-11-07 | 2002-03-12 | Advanced Research And Technologyinc | Nucleic acid encoding MIP-1α Lymphokine |
| US6362325B1 (en) | 1988-11-07 | 2002-03-26 | Advanced Research And Technology Institute, Inc. | Murine 4-1BB gene |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| WO1993007105A1 (en) | 1991-10-04 | 1993-04-15 | Iit Research Institute | Conversion of plastic waste to useful oils |
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| EP0571613B1 (en) | 1991-12-13 | 2003-09-17 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| ES2338321T3 (es) | 1992-08-21 | 2010-05-06 | Vrije Universiteit Brussel | Inmunoglobulinas desprovistas de cadenas ligeras. |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| CA2163012C (en) | 1994-03-17 | 2009-12-08 | Catherine A. Kettleborough | Anti-egfr single-chain fvs and anti-egfr antibodies |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US5773292A (en) | 1995-06-05 | 1998-06-30 | Cornell University | Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood |
| US7060808B1 (en) | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
| ATE218143T1 (de) | 1996-09-03 | 2002-06-15 | Gsf Forschungszentrum Umwelt | Verwendung bi-und trispezifischer antikörper zur induktion einer tumorimmunität |
| PL188749B1 (pl) | 1996-10-11 | 2005-04-29 | Bristol Myers Squibb Co | Zastosowanie przeciwciała anty-4-1BB i kompozycjaleku |
| US6670453B2 (en) * | 1997-10-27 | 2003-12-30 | Unilever Patent Holdings B.V. | Multivalent antigen-binding proteins |
| AU3596599A (en) | 1998-01-26 | 1999-08-09 | Unilever Plc | Method for producing antibody fragments |
| HUP9900956A2 (hu) | 1998-04-09 | 2002-04-29 | Aventis Pharma Deutschland Gmbh. | Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| AU2291700A (en) | 1999-01-19 | 2000-08-07 | Unilever Plc | Method for producing antibody fragments |
| DK1210428T3 (en) | 1999-08-23 | 2015-06-15 | Dana Farber Cancer Inst Inc | PD-1, a receptor for B7-4 AND USE THEREOF |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| JP4093757B2 (ja) | 1999-08-24 | 2008-06-04 | メダレックス， インコーポレイテッド | ヒトｃｔｌａ−４抗体およびその使用 |
| PT1223980E (pt) | 1999-10-28 | 2003-10-31 | Reinhold Hofbauer | Utilizacao de inibidores de csf-1 |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| US20060228364A1 (en) | 1999-12-24 | 2006-10-12 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| US7034121B2 (en) | 2000-01-27 | 2006-04-25 | Genetics Institue, Llc | Antibodies against CTLA4 |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| HK1047770A1 (zh) | 2000-02-24 | 2003-03-07 | Xcyte Therapies, Inc. | 细胞的同时刺激与浓缩 |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| ES2287130T3 (es) | 2000-05-12 | 2007-12-16 | Amgen Inc. | Polipeptidos para inhibir la proliferacion de celulas b y t inducida por april. |
| US20030190598A1 (en) | 2000-05-26 | 2003-10-09 | Jasmid Tanha | Single-domain antigen-binding antibody fragments derived from llama antibodies |
| WO2001096584A2 (en) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Materials and methods for the control of nematodes |
| DE60140461D1 (de) | 2000-09-11 | 2009-12-24 | Genzyme Corp | Muc1 extrazelluläre domäne und zusammensetzungen für krebsbehandlung, und davon abgeleitete verfahren |
| GB0100621D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VI |
| CN1294148C (zh) * | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
| CN1195779C (zh) | 2001-05-24 | 2005-04-06 | 中国科学院遗传与发育生物学研究所 | 抗人卵巢癌抗人cd3双特异性抗体 |
| US7666414B2 (en) | 2001-06-01 | 2010-02-23 | Cornell Research Foundation, Inc. | Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen |
| MXPA03011365A (es) | 2001-06-13 | 2005-03-07 | Genmab As | Anticuerpos monoclonales humanos para el receptor de factor de crecimiento epidermico (egfr). |
| US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| EP1433793A4 (en) | 2001-09-13 | 2006-01-25 | Inst Antibodies Co Ltd | METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY |
| EP1448588A4 (en) | 2001-10-23 | 2006-10-25 | Psma Dev Company L L C | ANTIBODIES AND MULTIMERS OF PSMA PROTEINS |
| US20050215472A1 (en) | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| WO2003064606A2 (en) | 2002-01-28 | 2003-08-07 | Medarex, Inc. | Human monoclonal antibodies to prostate specific membrane antigen (psma) |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| PT2371392E (pt) | 2002-05-02 | 2015-10-07 | Wyeth Holdings Llc | Conjugados de derivado da caliqueamicina - transportador |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| EP1600459A3 (en) * | 2002-06-28 | 2005-12-07 | Domantis Limited | Ligand |
| US6887673B2 (en) | 2002-07-30 | 2005-05-03 | Bristol-Myers Squibb Company | Humanized antibodies against human 4-1BB |
| MXPA05004022A (es) | 2002-10-17 | 2005-10-05 | Genmab As | Anticuerpos monoclonales humanos contra cd20. |
| AU2003283860B2 (en) | 2002-11-07 | 2009-09-17 | Erasmus Universiteit Rotterdam | Fret probes and methods for detecting interacting molecules |
| MXPA05004712A (es) | 2002-11-07 | 2005-11-23 | Immunogen Inc | Anticuerpos anti-cd33 y metodo para tratamiento de leucemia mieloide aguda utilizando los mismos. |
| EP1558650A2 (en) | 2002-11-08 | 2005-08-03 | Ablynx N.V. | Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders |
| US9320792B2 (en) | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
| JP2006519763A (ja) | 2002-11-08 | 2006-08-31 | アブリンクス エン．ヴェー． | 治療用ポリペプチドの投与法およびそのためのポリペプチド |
| ES2655912T3 (es) | 2002-11-08 | 2018-02-22 | Ablynx N.V. | Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos |
| GB0228210D0 (en) | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
| TWI335821B (en) | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
| BR0316880A (pt) | 2002-12-23 | 2005-10-25 | Wyeth Corp | Anticorpos contra pd-1 e usos dos mesmos |
| CN100509850C (zh) * | 2003-05-31 | 2009-07-08 | 麦克罗梅特股份公司 | 用于治疗b细胞相关疾病的包含双特异性抗cd3、抗cd19抗体构建体的药物组合物 |
| DK1629011T3 (da) | 2003-05-31 | 2010-05-03 | Micromet Ag | Humane anti-humane-DC3-bindingsmolekyler |
| EP1638510B1 (en) | 2003-07-01 | 2015-09-02 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
| AU2004253770C1 (en) | 2003-07-02 | 2010-04-15 | Innate Pharma | PAN-KIR2DL NK-receptor antibodies and their use in diagnostik and therapy |
| EP2292264A3 (en) | 2003-07-24 | 2012-12-19 | Innate Pharma | Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds |
| WO2005042743A2 (en) | 2003-08-18 | 2005-05-12 | Medimmune, Inc. | Humanization of antibodies |
| WO2005035575A2 (en) | 2003-08-22 | 2005-04-21 | Medimmune, Inc. | Humanization of antibodies |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| MXPA06004035A (es) | 2003-10-16 | 2006-08-31 | Micromet Ag | Aglutinantes cd3 de-inmunizados multi-especificos. |
| CN100376599C (zh) * | 2004-04-01 | 2008-03-26 | 北京安波特基因工程技术有限公司 | 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体 |
| WO2005118788A2 (en) | 2004-05-27 | 2005-12-15 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| US8921528B2 (en) | 2004-06-01 | 2014-12-30 | Domantis Limited | Bispecific fusion antibodies with enhanced serum half-life |
| JP2008512352A (ja) | 2004-07-17 | 2008-04-24 | イムクローン システムズ インコーポレイティド | 新規な四価の二重特異性抗体 |
| US20080069772A1 (en) | 2004-08-26 | 2008-03-20 | Eberhard-Karls-Universitaet Tuebingen Universitaetsklinikum | Treatment of transformed or infected biological cells |
| EP1634603A1 (de) | 2004-08-26 | 2006-03-15 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Behandlung von transformierten oder infizierten biologischen Zellen |
| FR2879605B1 (fr) | 2004-12-16 | 2008-10-17 | Centre Nat Rech Scient Cnrse | Production de formats d'anticorps et applications immunologiques de ces formats |
| DE602006003695D1 (de) | 2005-01-05 | 2009-01-02 | F Star Biotech Forsch & Entw | Synthetische Immunoglobulindomänen mit in Regionen des Moleküls, die sich von den die Komplementarität bestimmenden Bereichen unterscheiden, modifizierten Bindeeigenschaften |
| CN104829720B (zh) | 2005-01-06 | 2019-01-01 | 诺和诺德公司 | Kir结合剂和使用其的方法 |
| JP5855326B2 (ja) | 2005-01-06 | 2016-02-09 | ノヴォ ノルディスク アー／エス | 抗ｋｉｒ組み合わせ治療および方法 |
| ES2432091T5 (es) | 2005-03-25 | 2022-03-18 | Gitr Inc | Moléculas de unión GITR y usos de las mismas |
| US7833979B2 (en) | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
| US20060252096A1 (en) | 2005-04-26 | 2006-11-09 | Glycofi, Inc. | Single chain antibody with cleavable linker |
| CA2970873C (en) | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| MX363423B (es) | 2005-05-18 | 2019-03-22 | Ablynx Nv | Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor. |
| EP3243839A1 (en) | 2005-05-20 | 2017-11-15 | Ablynx N.V. | Improved nanobodies tm for the treatment of aggregation-mediated disorders |
| EP1726650A1 (en) | 2005-05-27 | 2006-11-29 | Universitätsklinikum Freiburg | Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| NZ597168A (en) | 2005-08-19 | 2013-07-26 | Abbott Lab | Dual variable domain immunoglobin and uses thereof |
| CA2625440C (en) | 2005-10-11 | 2023-06-13 | Micromet Ag | Compositions comprising cross-species-specific antibodies and uses thereof |
| AU2006301163B2 (en) | 2005-10-14 | 2012-02-23 | Innate Pharma | Compositions and methods for treating proliferative disorders |
| GB0521991D0 (en) | 2005-10-28 | 2005-12-07 | Univ Dundee | Siglec-9 binding agents |
| DK1951759T3 (da) | 2005-11-12 | 2010-05-10 | Lilly Co Eli | Anti-EGFR-antistoffer |
| WO2007062466A1 (en) | 2005-11-29 | 2007-06-07 | The University Of Sydney | Demibodies: dimerisation-activated therapeutic agents |
| US7498142B2 (en) | 2006-01-31 | 2009-03-03 | Yeda Research And Development Co., Ltd. | Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies |
| WO2007115230A2 (en) | 2006-03-30 | 2007-10-11 | University Of Medicine And Dentistry Of New Jersey | A strategy for homo- or hetero-dimerization of various proteins in solutions and in cells |
| CA2647282A1 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| US20070269422A1 (en) | 2006-05-17 | 2007-11-22 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| EP2057191A1 (en) | 2006-08-18 | 2009-05-13 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| CN101646689A (zh) | 2006-09-08 | 2010-02-10 | 埃博灵克斯股份有限公司 | 具有长半衰期的血清清蛋白结合蛋白 |
| CN101557817A (zh) | 2006-09-14 | 2009-10-14 | 人类基因科学公司 | 清蛋白融合蛋白 |
| US20100166734A1 (en) | 2006-12-20 | 2010-07-01 | Edward Dolk | Oral delivery of polypeptides |
| CN105037549B (zh) | 2007-01-11 | 2018-09-28 | 诺和诺德公司 | 抗-kir抗体、制剂及其应用 |
| US20100150918A1 (en) | 2007-04-03 | 2010-06-17 | Micromet Ag | Cross-species-specific binding domain |
| WO2008119566A2 (en) * | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific bispecific binders |
| JP2008278814A (ja) | 2007-05-11 | 2008-11-20 | Igaku Seibutsugaku Kenkyusho:Kk | アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用 |
| ES2663512T3 (es) | 2007-05-24 | 2018-04-13 | Ablynx N.V. | Secuencias de aminoácidos dirigidas contra RANK-L y polipéptidos que comprenden las mismas para el tratamiento de enfermedades y trastornos óseos |
| AU2008260498B2 (en) | 2007-05-30 | 2012-11-29 | Xencor, Inc. | Methods and compositions for inhibiting CD32b expressing cells |
| SI2170959T1 (sl) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | Protitelesa proti receptorjem pd-1 za humano programirano smrt |
| EP2014680A1 (en) | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
| PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| EP2170960B1 (en) | 2007-07-13 | 2015-07-29 | Bac Ip B.V. | Single-domain antigen-binding proteins that bind mammalian igg |
| EP3492488A1 (en) | 2007-08-22 | 2019-06-05 | The Regents of The University of California | Activatable binding polypeptides and methods of identification and use thereof |
| EP2195342A1 (en) | 2007-09-07 | 2010-06-16 | Ablynx N.V. | Binding molecules with multiple binding sites, compositions comprising the same and uses thereof |
| US7982016B2 (en) * | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| ES2622460T3 (es) | 2007-09-26 | 2017-07-06 | Ucb Biopharma Sprl | Fusiones de anticuerpos con doble especificidad |
| KR20100110864A (ko) | 2008-01-24 | 2010-10-13 | 노보 노르디스크 에이/에스 | 인간화된 항-인간 ｎｋｇ2ａ 모노클로날 항체 |
| BRPI0907718A2 (pt) | 2008-02-11 | 2017-06-13 | Curetech Ltd | método para tratar um tumor, método para melhorar a tolerabilidade a pelo menos um agente quimiterápico, método para aumentar a sobrevida de um indivíduo que tem um tumor, método para reduzir ou prevenir recidiva tumoral, uso de um anticorpo monoclonal humanizado ou seu fragmento e anticorpo monoclonal humanizado ou seu fragmento |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| CN102112155B (zh) | 2008-06-05 | 2016-08-10 | 埃博灵克斯股份有限公司 | 针对病毒包膜蛋白的氨基酸序列和用于治疗病毒疾病的包含其的多肽 |
| US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| US20110177070A1 (en) | 2008-07-02 | 2011-07-21 | Emergent Product Development Seatlle, LLC | TGF-Beta Antagonist Multi-Target Binding Proteins |
| US8444976B2 (en) | 2008-07-02 | 2013-05-21 | Argen-X B.V. | Antigen binding polypeptides |
| DE102008036127A1 (de) | 2008-08-01 | 2010-02-04 | Emitec Gesellschaft Für Emissionstechnologie Mbh | Verfahren zum Betrieb einer Abgasanlage mit Lambda-Regelung |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| WO2010027423A2 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| EA201170375A1 (ru) | 2008-08-25 | 2012-03-30 | Эмплиммьюн, Инк. | Антагонисты pd-1 и способы их применения |
| ME02485B (me) | 2008-10-01 | 2017-02-20 | Amgen Res Munich Gmbh | Bispecifično jednolančano protutijelo psmaxcd3 s međuvrsnom specifičnošću |
| WO2010037837A2 (en) | 2008-10-01 | 2010-04-08 | Micromet Ag | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
| WO2010037838A2 (en) | 2008-10-01 | 2010-04-08 | Micromet Ag | Cross-species-specific single domain bispecific single chain antibody |
| CA2740561C (en) | 2008-10-14 | 2021-01-19 | National Research Council Of Canada | Bsa-specific antibodies |
| WO2010065939A1 (en) | 2008-12-05 | 2010-06-10 | Indiana University Research & Technology Corporation | Combination therapy to enhace nk cell mediated cytotoxicty |
| JP2012511033A (ja) | 2008-12-08 | 2012-05-17 | テゴファーム コーポレーション | 多価化合物の可逆阻害用マスキングリガンド |
| FI4209510T3 (fi) | 2008-12-09 | 2024-03-22 | Hoffmann La Roche | Anti-PD-L1-vasta-aineita ja niiden käyttö T-solutoiminnan tehostamiseksi |
| US9345787B2 (en) | 2008-12-22 | 2016-05-24 | Targovax Oy | Adenoviral vectors and methods and uses related thereto |
| AU2010203353B2 (en) | 2009-01-12 | 2016-06-16 | Cytomx Therapeutics, Inc | Modified antibody compositions, methods of making and using thereof |
| EP2210902A1 (en) | 2009-01-14 | 2010-07-28 | TcL Pharma | Recombinant monovalent antibodies |
| ES2629337T3 (es) | 2009-02-09 | 2017-08-08 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos |
| CN102781470B (zh) | 2009-03-05 | 2016-01-20 | Abbvie公司 | Il-17结合蛋白 |
| RU2595409C2 (ru) | 2009-09-03 | 2016-08-27 | Мерк Шарп И Доум Корп., | Анти-gitr-антитела |
| UY32917A (es) | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Moléculas de unión a dll-4 |
| WO2011051327A2 (en) | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| BR112012012983A2 (pt) * | 2009-12-04 | 2020-09-15 | Genentech Inc | método para sintetizar um anticorpo multiespecífico, método para sintetizar um painel de anticorpos multiespecíficos, método para sintetizar um análogo de anticorpo, método para sintetizar um painel de análogos de anticorpo e composições |
| EP2332994A1 (en) | 2009-12-09 | 2011-06-15 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Trispecific therapeutics against acute myeloid leukaemia |
| SI2510010T1 (sl) | 2009-12-10 | 2016-02-29 | F. Hoffmann-La Roche Ag | Protitelesa, vezavna na ekstracelično domeno 4 humanega csf1r in njihova uporaba |
| TW201125583A (en) | 2009-12-23 | 2011-08-01 | Bioalliance Cv | Anti-EpCAM antibodies that induce apoptosis of cancer cells and methods using same |
| US20130089554A1 (en) | 2009-12-29 | 2013-04-11 | Emergent Product Development Seattle, Llc | RON Binding Constructs and Methods of Use Thereof |
| GB2476681B (en) | 2010-01-04 | 2012-04-04 | Argen X Bv | Humanized camelid VH, VK and VL immunoglobulin domains |
| WO2011093097A1 (ja) | 2010-01-29 | 2011-08-04 | 株式会社未来創薬研究所 | 抗dll3抗体 |
| RU2617966C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
| JP2013521765A (ja) | 2010-03-05 | 2013-06-13 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| US10706955B2 (en) | 2010-03-23 | 2020-07-07 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| WO2011117423A1 (en) | 2010-03-26 | 2011-09-29 | Ablynx N.V. | Immunoglobulin single variable domains directed against cxcr7 |
| US9556273B2 (en) | 2010-03-29 | 2017-01-31 | Vib Vzw | Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| PL2581113T3 (pl) | 2010-06-11 | 2018-11-30 | Kyowa Hakko Kirin Co., Ltd. | Przeciwciało anty-tim-3 |
| PL391627A1 (pl) | 2010-06-25 | 2012-01-02 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Przeciwnowotworowe białko fuzyjne |
| WO2012009568A2 (en) | 2010-07-16 | 2012-01-19 | Adimab, Llc | Antibody libraries |
| EP2603237A4 (en) | 2010-08-12 | 2014-05-21 | Theraclone Sciences Inc | ANTI-HEMAGGLUTININE ANTIBODY COMPOSITIONS AND METHOD FOR THEIR USE |
| CN103068847B (zh) | 2010-08-24 | 2019-05-07 | 罗切格利卡特公司 | 可活化的双特异性抗体 |
| JP5758004B2 (ja) | 2010-08-24 | 2015-08-05 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ジスルフィドによって安定化されたＦｖ断片を含む二重特異性抗体 |
| WO2012042026A1 (en) | 2010-09-30 | 2012-04-05 | Ablynx Nv | Biological materials related to c-met |
| US20130273055A1 (en) | 2010-11-16 | 2013-10-17 | Eric Borges | Agents and methods for treating diseases that correlate with bcma expression |
| EP2643350A4 (en) | 2010-11-22 | 2015-01-07 | Innate Pharma Sa | TREATMENTS WITH NK CELL MODULATION AND METHOD FOR THE TREATMENT OF HEMATOLOGICAL MALIGNOMES |
| JP6322413B2 (ja) | 2011-03-10 | 2018-05-09 | プロヴェクタス ファーマテック，インク． | 改善されたがん治療のための局所および全身性免疫修飾療法の組み合わせ |
| EP2684953B1 (en) | 2011-03-11 | 2017-06-28 | Kaneka Corporation | Modified aminotransferase, gene thereof, and method for producing optically active amino compound using same |
| CN106039306A (zh) | 2011-03-30 | 2016-10-26 | 埃博灵克斯股份有限公司 | 使用针对TNFα的单结构域抗体治疗免疫病症的方法 |
| IL285335B2 (en) | 2011-04-08 | 2023-12-01 | Us Health | Chimeric antigen receptors against epidermal growth factor receptor variant III and their use in cancer treatment |
| US20140170149A1 (en) * | 2011-04-20 | 2014-06-19 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
| RS57324B1 (sr) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antitela i drugi molekuli koji vezuju b7-h1 i pd-1 |
| US8846042B2 (en) | 2011-05-16 | 2014-09-30 | Fabion Pharmaceuticals, Inc. | Multi-specific FAB fusion proteins and methods of use |
| UA111612C2 (uk) | 2011-05-21 | 2016-05-25 | Макродженікс, Інк. | Домени, які зв'язуються з деімунізованою сироваткою, і їхнє застосування для збільшення часу напівжиття в сироватці |
| EA036545B1 (ru) | 2011-05-25 | 2020-11-20 | Иннейт Фарма, С.А. | Анти-kir антитела для лечения воспалительных заболеваний |
| EP3693394A1 (en) | 2011-05-27 | 2020-08-12 | Glaxo Group Limited | Antigen binding proteins |
| PT2723771T (pt) | 2011-06-23 | 2019-12-11 | Ablynx Nv | Proteínas de ligação à albumina sérica |
| US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| EP2753644A1 (en) | 2011-09-09 | 2014-07-16 | Universiteit Utrecht Holding B.V. | Broadly neutralizing vhh against hiv-1 |
| WO2013039954A1 (en) | 2011-09-14 | 2013-03-21 | Sanofi | Anti-gitr antibodies |
| CA2846436A1 (en) | 2011-09-23 | 2013-03-28 | Universitat Stuttgart | Serum half-life extension using immunoglobulin binding domains |
| CN103889451B (zh) | 2011-09-30 | 2016-06-29 | 埃博灵克斯股份有限公司 | 与C-Met相关的生物物质 |
| CN103857670B (zh) | 2011-10-11 | 2016-03-23 | Ucb医药有限公司 | 2-氧代-哌啶基衍生物 |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| EP3763741A1 (en) | 2011-11-28 | 2021-01-13 | Merck Patent GmbH | Anti-pd-l1 antibodies and uses thereof |
| MX356337B (es) | 2011-12-15 | 2018-05-23 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| EP2790723A1 (en) | 2011-12-16 | 2014-10-22 | Pfizer Inc | Combination of inotuzumab ozogamicin and torisel for the treatment of cancer |
| EP2793918B1 (en) | 2011-12-19 | 2019-09-11 | The Rockefeller University | Hdc-sign binding peptides |
| CA2861003C (en) | 2012-01-13 | 2023-03-28 | Julius-Maximilians-Universitat Wurzburg | Dual antigen-induced bipartite functional complementation |
| US9670275B2 (en) | 2012-01-23 | 2017-06-06 | Ablynx N.V. | Sequences directed against hepatocyte growth factor (HGF) and polypeptides comprising the same for the treatment of cancers and/or tumors |
| MX2014008961A (es) | 2012-02-06 | 2014-10-14 | Genentech Inc | Composiciones y metodos para utilizar inhibidores de csf1r. |
| AU2013222267A1 (en) | 2012-02-22 | 2014-07-31 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer |
| SI2817338T1 (sl) | 2012-02-24 | 2017-11-30 | Abbvie Stemcentrx Llc | Modulatorji DLL3 in postopki uporabe |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| WO2013128027A1 (en) | 2012-03-01 | 2013-09-06 | Amgen Research (Munich) Gmbh | Long life polypeptide binding molecules |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| SG11201406129QA (en) | 2012-03-30 | 2014-10-30 | Bayer Healthcare Llc | Protease-regulated antibodies |
| CN104487587A (zh) | 2012-04-20 | 2015-04-01 | 新兴产品开发西雅图有限公司 | Cd3结合多肽 |
| RU2713121C2 (ru) | 2012-04-27 | 2020-02-03 | Сайтомкс Терапьютикс, Инк. | Активируемые антитела, которые связываются с рецептором эпидермального фактора роста, и способы их применения |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| KR102418979B1 (ko) | 2012-05-15 | 2022-07-11 | 브리스톨-마이어스 스큅 컴퍼니 | Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법 |
| KR101549637B1 (ko) | 2012-06-08 | 2015-09-03 | 국립암센터 | 신규한 Ｔｈ1 세포 전환용 에피토프 및 이의 용도 |
| US9856314B2 (en) | 2012-06-22 | 2018-01-02 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and methods of using the same |
| WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| BR112015000798A2 (pt) | 2012-07-13 | 2017-06-27 | Zymeworks Inc | heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3 |
| CN112587658A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| SG10201906328RA (en) | 2012-08-31 | 2019-08-27 | Five Prime Therapeutics Inc | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| AU2013310839B2 (en) | 2012-08-31 | 2017-06-01 | Argenx Bvba | Highly diverse combinatorial antibody libraries |
| KR101963231B1 (ko) | 2012-09-11 | 2019-03-28 | 삼성전자주식회사 | 이중특이 항체의 제작을 위한 단백질 복합체 및 이를 이용한 이중특이 항체 제조 방법 |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| ES2666131T3 (es) | 2012-09-27 | 2018-05-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anticuerpos de mesotelina y métodos para provocar una potente actividad antitumoral |
| DK2904011T3 (en) | 2012-10-02 | 2017-12-04 | Bristol Myers Squibb Co | COMBINATION OF ANTI-KIR ANTIBODIES AND ANTI-PD-1 ANTIBODIES FOR TREATMENT OF CANCER |
| SMT201800335T1 (it) * | 2012-11-06 | 2018-09-13 | Bayer Pharma AG | Formulazione di attivatori bispecifici per linfociti t (bite) |
| US9243058B2 (en) | 2012-12-07 | 2016-01-26 | Amgen, Inc. | BCMA antigen binding proteins |
| HUE047221T2 (hu) | 2012-12-17 | 2020-04-28 | Trillium Therapeutics Inc | A CD47+ kóros sejtek kezelése SIRP alfa-FC fúziókkal |
| JO3519B1 (ar) | 2013-01-25 | 2020-07-05 | Amgen Inc | تركيبات أجسام مضادة لأجل cdh19 و cd3 |
| GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| KR20160037130A (ko) | 2013-02-22 | 2016-04-05 | 스템센트알엑스 인코포레이티드 | 신규한 항체 접합체 및 이의 용도 |
| WO2014132072A1 (en) | 2013-02-28 | 2014-09-04 | University Court Of The University Of Edinburgh | Csf1 therapeutics |
| AU2014225788B2 (en) | 2013-03-05 | 2018-03-29 | Baylor College Of Medicine | Engager cells for immunotherapy |
| JP6464140B2 (ja) | 2013-03-13 | 2019-02-06 | ヘルス リサーチ インコーポレイテッドＨｅａｌｔｈ Ｒｅｓｅａｒｃｈ， Ｉｎｃ． | 腫瘍抗原を直接認識するために組換えｔ細胞レセプターを使用するための組成物及び方法 |
| CN105209493B (zh) | 2013-03-14 | 2019-05-03 | 德克萨斯州大学系统董事会 | 用于诊断和治疗用途的her3特异性单克隆抗体 |
| US10351626B2 (en) | 2013-03-14 | 2019-07-16 | The Scripps Research Institute | Targeting agent antibody conjugates and uses thereof |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| US20140308285A1 (en) | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
| EP3424952A1 (en) * | 2013-03-15 | 2019-01-09 | Amgen, Inc | Heterodimeric bispecific antibodies |
| TW201525001A (zh) | 2013-03-15 | 2015-07-01 | Amgen Res Munich Gmbh | 包含ｎ－端ａｂｐ之單鏈結合分子 |
| TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| CA2913051C (en) | 2013-05-28 | 2023-09-05 | Dcb-Usa Llc | Antibody locker for the inactivation of protein drug |
| CA2918795A1 (en) | 2013-07-25 | 2015-01-29 | Cytomx Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
| NZ717476A (en) | 2013-08-01 | 2022-04-29 | Univ Catholique Louvain | Anti-garp protein and uses thereof |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| JP2016531914A (ja) | 2013-08-28 | 2016-10-13 | ステムセントリックス， インコーポレイテッド | 操作された抗ｄｌｌ３コンジュゲートおよび使用方法 |
| TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
| ES2927567T3 (es) | 2013-09-13 | 2022-11-08 | Beigene Switzerland Gmbh | Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico |
| EA036902B1 (ru) | 2013-09-20 | 2021-01-13 | Бристол-Майерс Сквибб Компани | Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей |
| CN107041146A (zh) | 2013-09-24 | 2017-08-11 | 华盛顿大学商业化中心 | 桥粒芯糖蛋白2(dsg2)结合蛋白质及其用途 |
| PT3049439T (pt) | 2013-09-26 | 2020-03-31 | Ablynx Nv | Nanocorpos biespecíficos |
| US20160263087A1 (en) | 2013-11-08 | 2016-09-15 | Iteos Therapeutics | Novel 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use |
| US9126984B2 (en) | 2013-11-08 | 2015-09-08 | Iteos Therapeutics | 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use |
| US9931347B2 (en) | 2013-12-03 | 2018-04-03 | Iomet Pharma Ltd. | Pharmaceutical compound |
| JP6706578B2 (ja) | 2013-12-30 | 2020-06-10 | エピムアブ バイオセラピューティクス インコーポレイテッド | タンデム型Ｆａｂ免疫グロブリン及びその使用 |
| JP2017505346A (ja) | 2014-02-12 | 2017-02-16 | アイティーオス セラペウティクス | 新規な３−（インドール−３−イル）−ピリジン誘導体、医薬組成物、および使用方法 |
| WO2015127407A1 (en) | 2014-02-21 | 2015-08-27 | Stemcentrx, Inc. | Anti-dll3 antibodies and drug conjugates for use in melanoma |
| CN106163547A (zh) | 2014-03-15 | 2016-11-23 | 诺华股份有限公司 | 使用嵌合抗原受体治疗癌症 |
| CA2942761A1 (en) | 2014-03-18 | 2015-09-24 | Iteos Therapeutics | Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
| WO2015145360A1 (en) | 2014-03-24 | 2015-10-01 | Glennie Martin J | Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof |
| WO2015146437A1 (ja) | 2014-03-25 | 2015-10-01 | 国立大学法人東北大学 | 高機能性ＩｇＧ２型二重特異性抗体 |
| EP3708579B1 (en) | 2014-04-01 | 2024-05-01 | Biontech Cell & Gene Therapies Gmbh | Claudin-6-specific immunoreceptors and t cell epitopes |
| UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| CN106715417B (zh) | 2014-04-04 | 2020-01-14 | 爱欧梅特制药公司 | 药物中使用的吲哚衍生物 |
| CN113501880A (zh) | 2014-05-02 | 2021-10-15 | 动量制药公司 | 涉及工程化Fc构建体的组合物和方法 |
| UY36122A (es) | 2014-05-15 | 2016-01-08 | Iteos Therapeutics | ?derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1? |
| IL293212B2 (en) | 2014-05-28 | 2023-12-01 | Memorial Sloan Kettering Cancer Center | Anti-GITR antibodies and methods of using them |
| PE20170765A1 (es) | 2014-05-29 | 2017-07-04 | Macrogenics Inc | Moleculas de union tri-especificas y metodos de uso de las mismas |
| JP6449338B2 (ja) | 2014-06-06 | 2019-01-09 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用 |
| GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| BR112017001183A2 (pt) | 2014-07-21 | 2017-11-28 | Novartis Ag | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado |
| CN107108738A (zh) | 2014-07-25 | 2017-08-29 | 西托姆克斯治疗公司 | 抗cd3抗体、可活化抗cd3抗体、多特异性抗cd3抗体、多特异性可活化抗cd3抗体及其使用方法 |
| US20170275373A1 (en) | 2014-07-31 | 2017-09-28 | Amgen Research (Munich) Gmbh | Bispecific single chain antibody construct with enhanced tissue distribution |
| UY36245A (es) | 2014-07-31 | 2016-01-29 | Amgen Res Munich Gmbh | Constructos de anticuerpos para cdh19 y cd3 |
| GB201414730D0 (en) | 2014-08-19 | 2014-10-01 | Tpp Global Dev Ltd | Pharmaceutical compound |
| KR20170051462A (ko) | 2014-08-28 | 2017-05-11 | 아카데미슈 지켄후이스 라이덴 | Ｃｄ９４／ｎｋｇ２ａ 및／또는 ｃｄ９４／ｎｋｇ２ｂ 항체, 백신 조합물 |
| RS60305B1 (sr) | 2014-09-05 | 2020-07-31 | Janssen Pharmaceutica Nv | Agensi koji vezuju cd123 i njihove upotrebe |
| CN105471609B (zh) | 2014-09-05 | 2019-04-05 | 华为技术有限公司 | 一种用于配置业务的方法和装置 |
| DK3191517T3 (da) | 2014-09-10 | 2021-01-25 | Innate Pharma | Krydsreaktive siglec-antistoffer |
| KR20240141862A (ko) | 2014-09-16 | 2024-09-27 | 이나뜨 파르마 에스.에이. | 항-ｎｋｇ2ａ 항체를 사용한 치료 요법 |
| WO2016046778A2 (en) | 2014-09-25 | 2016-03-31 | Amgen Inc | Protease-activatable bispecific proteins |
| EP3204491A1 (en) | 2014-10-07 | 2017-08-16 | Cellectis | Method for modulating car-induced immune cells activity |
| GB201419579D0 (en) | 2014-11-03 | 2014-12-17 | Iomet Pharma Ltd | Pharmaceutical compound |
| EP3215156B1 (en) | 2014-11-03 | 2025-09-24 | Iomet Pharma Ltd. | Inhibitors of tryptophan-2,3-dioxygenase or indoleamine-2,3-dioxygenase |
| HRP20210888T4 (hr) | 2014-11-10 | 2024-12-06 | Medimmune Limited | Vezujuće molekule specifične za cd73 i njihova upotreba |
| CN107406512A (zh) | 2014-11-26 | 2017-11-28 | Xencor公司 | 结合cd3和cd38的异二聚体抗体 |
| EP3029068A1 (en) | 2014-12-03 | 2016-06-08 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases |
| US11001625B2 (en) | 2014-12-10 | 2021-05-11 | Tufts University | VHH based binding antibodies for anthrax and botulinum toxins and methods of making and using therefor |
| US10428155B2 (en) * | 2014-12-22 | 2019-10-01 | Xencor, Inc. | Trispecific antibodies |
| JP2018503399A (ja) | 2015-01-14 | 2018-02-08 | コンパス セラピューティクス リミテッド ライアビリティ カンパニー | 多特異性免疫調節抗原結合構築物 |
| WO2016125017A1 (en) | 2015-02-03 | 2016-08-11 | Universite Catholique De Louvain | Anti-garp protein and uses thereof |
| MY186585A (en) | 2015-02-05 | 2021-07-28 | Janssen Vaccines & Prevention Bv | Binding molecules directed against influenza hemagglutinin and uses thereof |
| WO2016130819A2 (en) | 2015-02-11 | 2016-08-18 | Emergent Product Development Seattle Llc | Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins |
| EP3978929A1 (en) | 2015-02-19 | 2022-04-06 | Compugen Ltd. | Pvrig polypeptides and methods of treatment |
| IL254039B2 (en) | 2015-02-19 | 2023-12-01 | Compugen Ltd | Anti-pvrig antibodies and methods of use |
| MA41613A (fr) | 2015-02-23 | 2018-01-02 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs |
| EP3271354A1 (en) | 2015-03-17 | 2018-01-24 | Pfizer Inc | Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
| WO2016171999A2 (en) | 2015-04-22 | 2016-10-27 | AgBiome, Inc. | Pesticidal genes and methods of use |
| HK1252158A1 (zh) | 2015-05-01 | 2019-05-17 | Genentech, Inc. | 掩蔽抗cd3抗体和使用方法 |
| CA2985125A1 (en) | 2015-05-06 | 2016-11-10 | Janssen Biotech, Inc. | Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof |
| DK3294319T3 (da) | 2015-05-13 | 2024-07-22 | Ablynx Nv | T-celle-rekrutterende polypeptider baseret på cd3-reaktivitet |
| JP6841754B2 (ja) | 2015-05-13 | 2021-03-10 | 中外製薬株式会社 | 多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法 |
| WO2016181349A1 (en) | 2015-05-14 | 2016-11-17 | Pfizer Inc. | Combinations comprising a pyrrolidine-2,5-dione ido1 inhibitor and an anti-body |
| ES2881683T3 (es) | 2015-05-21 | 2021-11-30 | Full Spectrum Genetics Inc | Procedimiento para mejorar las características de las proteínas |
| AU2016263808B2 (en) | 2015-05-21 | 2019-01-03 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| CN108271390A (zh) | 2015-06-03 | 2018-07-10 | 农业生物群落股份有限公司 | 杀虫基因和使用方法 |
| JP2018518972A (ja) | 2015-06-26 | 2018-07-19 | ユニバーシティ オブ サザン カリフォルニア | 腫瘍特異的活性化のためのマスキングキメラ抗原受容体ｔ細胞 |
| GB201511790D0 (en) | 2015-07-06 | 2015-08-19 | Iomet Pharma Ltd | Pharmaceutical compound |
| MX2018000344A (es) | 2015-07-10 | 2018-03-14 | Merus Nv | Anticuerpo que se une a grupo de diferenciacion 3 (cd3) humano. |
| CA2991799A1 (en) | 2015-07-15 | 2017-01-19 | Zymeworks Inc. | Drug-conjugated bi-specific antigen-binding constructs |
| TWI793062B (zh) | 2015-07-31 | 2023-02-21 | 德商安美基研究（慕尼黑）公司 | Ｄｌｌ３及ｃｄ３抗體構築體 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| HUE048939T2 (hu) | 2015-08-03 | 2020-09-28 | Engmab Sarl | Human B sejt érési antigén elleni monoklonális antitestek (BCMA) |
| WO2017027392A1 (en) | 2015-08-07 | 2017-02-16 | Novartis Ag | Treatment of cancer using chimeric cd3 receptor proteins |
| CA2994917A1 (en) | 2015-08-10 | 2017-02-16 | Pfizer Inc. | 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
| WO2017025698A1 (en) | 2015-08-11 | 2017-02-16 | Queen Mary University Of London | Bispecific, cleavable antibodies |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| JO3799B1 (ar) | 2015-08-17 | 2021-01-31 | Janssen Pharmaceutica Nv | الأجسام المضادة ل bcma، جزيئات ربط الانتيجين ثنائية التحديد التي تربط bcma و cd3، و استخداماتها |
| MX2018002166A (es) | 2015-08-20 | 2018-09-12 | Abbvie Stemcentrx Llc | Conjugados anticuerpo anti-dll3-farmaco y metodos de uso. |
| CN106519037B (zh) | 2015-09-11 | 2019-07-23 | 科济生物医药（上海）有限公司 | 可活化的嵌合受体 |
| KR102776730B1 (ko) | 2015-09-24 | 2025-03-05 | 다이이찌 산쿄 가부시키가이샤 | 항 garp 항체 |
| EP3368575B1 (en) | 2015-10-29 | 2025-05-07 | Alector LLC | Anti-siglec-9 antibodies and methods of use thereof |
| JP2018537970A (ja) | 2015-11-05 | 2018-12-27 | シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ | 養子ｔ細胞療法のための細胞を調製する方法 |
| HK1256367A1 (zh) | 2015-11-19 | 2019-09-20 | 豪夫迈‧罗氏有限公司 | 使用b-raf抑制剂和免疫检查点抑制剂治疗癌症的方法 |
| PL3377103T5 (pl) | 2015-11-19 | 2025-07-07 | Revitope Limited | Komplementacja funkcjonalnego fragmentu przeciwciała dla dwuskładnikowego układu do przekierowanego zabijania niepożądanych komórek |
| CN121294437A (zh) | 2015-12-04 | 2026-01-09 | 诺华股份有限公司 | 用于免疫肿瘤学的组合物和方法 |
| EP3402516A4 (en) | 2016-01-12 | 2020-01-08 | Palleon Pharmaceuticals Inc. | USE OF ANTIBODIES DIRECTED AGAINST SIGLEC-7 OR SIGLEC-9 IN THE TREATMENT OF CANCER |
| US9624185B1 (en) | 2016-01-20 | 2017-04-18 | Yong Xu | Method for preparing IDO inhibitor epacadostat |
| US10301391B2 (en) | 2016-02-03 | 2019-05-28 | Amgen Research (Munich) Gmbh | BCMA and CD3 bispecific T cell engaging antibody constructs |
| EP3411380A4 (en) | 2016-02-03 | 2020-01-22 | Youhealth Biotech, Limited | Compounds for treating eye disorders or diseases |
| CN109071667A (zh) | 2016-03-08 | 2018-12-21 | 马弗里克治疗公司 | 可诱导性结合蛋白和使用方法 |
| EP3430058A4 (en) | 2016-03-15 | 2019-10-23 | Generon (Shanghai) Corporation Ltd. | MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF |
| WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
| SG11201808085WA (en) | 2016-03-22 | 2018-10-30 | Hoffmann La Roche | Protease-activated t cell bispecific molecules |
| EP3436480A4 (en) | 2016-03-30 | 2019-11-27 | Musc Foundation for Research Development | METHOD FOR THE TREATMENT AND DIAGNOSIS OF CANCER BY TARGETING GLYCOPROTEIN A REPETITION PREDOMINANT (GARP) AND FOR EFFECTIVE IMMUNOTHERAPY ALONE OR IN COMBINATION |
| WO2017201442A1 (en) | 2016-05-20 | 2017-11-23 | Abbvie Stemcentrx Llc | Anti-dll3 drug conjugates for treating tumors at risk of neuroendocrine transition |
| MX2018014228A (es) | 2016-05-20 | 2019-08-12 | Harpoon Therapeutics Inc | Proteina de union de albumina sérica de dominio unico. |
| MX2018014227A (es) | 2016-05-20 | 2019-08-22 | Harpoon Therapeutics Inc | Proteinas de union de cadena unica de fragmento variable cd3. |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| EP3464365A1 (en) | 2016-06-01 | 2019-04-10 | Xencor, Inc. | Bispecific antibodies that bind cd123 and cd3 |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| WO2018017864A2 (en) | 2016-07-20 | 2018-01-25 | Oncomed Pharmaceuticals, Inc. | Pvrig-binding agents and uses thereof |
| TW201815825A (zh) | 2016-07-21 | 2018-05-01 | 財團法人生物技術開發中心 | 經修飾之抗原結合fab片段及包含其之抗原結合分子 |
| CA3032498A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2018027203A1 (en) | 2016-08-05 | 2018-02-08 | Allakos, Inc. | Anti-siglec-7 antibodies for the treatment of cancer |
| US11324744B2 (en) | 2016-08-08 | 2022-05-10 | Acetylon Pharmaceuticals Inc. | Methods of use and pharmaceutical combinations of histone deacetylase inhibitors and CD20 inhibitory antibodies |
| LT3347379T (lt) | 2016-08-17 | 2020-05-11 | Compugen Ltd. | Anti-tigit antikūnai, anti-pvrig antikūnai ir jų kombinacijos |
| US20190218294A1 (en) | 2016-09-09 | 2019-07-18 | Bristol-Myers Squibb Company | Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment |
| WO2018071777A1 (en) | 2016-10-14 | 2018-04-19 | Harpoon Therapeutics, Inc. | Innate immune cell trispecific binding proteins and methods of use |
| EP3526246A1 (en) | 2016-10-17 | 2019-08-21 | Vetoquinol SA | Modified antibody constant region |
| WO2018075359A1 (en) | 2016-10-18 | 2018-04-26 | Boger Henry William | Wireless power transfer for process control |
| EP3689419A1 (en) | 2016-11-01 | 2020-08-05 | AnaptysBio, Inc. | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| KR102687833B1 (ko) | 2016-11-02 | 2024-07-24 | 브리스톨-마이어스 스큅 컴퍼니 | 다발성 골수종 치료를 위한 bcma 및 cd3에 대응하는 이중 특이적 항체 및 면역학적 약물의 복합용도 |
| AU2017363300A1 (en) | 2016-11-23 | 2019-06-20 | Harpoon Therapeutics, Inc. | Prostate specific membrane antigen binding protein |
| WO2018098356A1 (en) | 2016-11-23 | 2018-05-31 | Harpoon Therapeutics, Inc. | Psma targeting trispecific proteins and methods of use |
| JOP20190133A1 (ar) | 2016-12-08 | 2019-06-02 | Innovent Biologics Suzhou Co Ltd | أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1 |
| EP3551659A1 (en) | 2016-12-08 | 2019-10-16 | Eli Lilly and Company | Anti-tim-3 antibodies for combination with anti-pd-l1 antibodies |
| RU2754058C2 (ru) | 2016-12-13 | 2021-08-26 | Астеллас Фарма Инк. | Антитело к cd73 человека |
| WO2018115859A1 (en) | 2016-12-20 | 2018-06-28 | Kymab Limited | Multispecific antibody with combination therapy for immuno-oncology |
| HRP20211642T1 (hr) | 2016-12-22 | 2022-01-21 | Amgen Inc. | Derivati benzizotiazola, izotiazolo[3,4-b]piridina, kinazolina, ftalazina, pirido[2,3-d]piridazina i pirido[2,3-d]pirimidina kao inhibitori kras g12c za liječenje raka pluća, gušterače ili kolorektalnog karcinoma |
| WO2018136725A1 (en) | 2017-01-19 | 2018-07-26 | Harpoon Therapeutics, Inc. | Innate immune cell inducible binding proteins and methods of use |
| CN108341872B (zh) | 2017-01-23 | 2020-05-19 | 科济生物医药（上海）有限公司 | 靶向bcma的抗体及其应用 |
| US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| WO2018160671A1 (en) | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Targeted checkpoint inhibitors and methods of use |
| US20180303952A1 (en) | 2017-03-09 | 2018-10-25 | Cytomx Therapeutics, Inc. | Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof |
| WO2018183366A1 (en) | 2017-03-28 | 2018-10-04 | Syndax Pharmaceuticals, Inc. | Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy |
| EP3619234A4 (en) | 2017-05-03 | 2021-05-26 | Harpoon Therapeutics, Inc. | COMPOSITIONS AND PROCEDURES FOR ADOPTIVE CELL THERAPIES |
| IL300964A (en) | 2017-05-12 | 2023-04-01 | Harpoon Therapeutics Inc | mesothelin binding proteins |
| US20200270362A1 (en) | 2017-05-12 | 2020-08-27 | Harpoon Therapeutics, Inc. | Msln targeting trispecific proteins and methods of use |
| KR20200026810A (ko) | 2017-05-12 | 2020-03-11 | 하푼 테라퓨틱스, 인크. | Msln 표적화 삼중 특이적 단백질 및 사용 방법 |
| BR112019025243A2 (pt) | 2017-06-02 | 2020-07-14 | Pfizer Inc. | anticorpos específicos para flt3 e usos dos mesmos |
| EP3652207A1 (en) | 2017-07-10 | 2020-05-20 | Innate Pharma | Combination therapy using antibody to human siglec-9 and antibody to human nkg2a for treating cancer |
| WO2019011855A1 (en) | 2017-07-10 | 2019-01-17 | Innate Pharma | ANTIBODIES NEUTRALIZING SIGLEC-9 |
| KR20250009550A (ko) | 2017-08-01 | 2025-01-17 | 메디뮨 엘엘씨 | Bcma 단클론 항체-약물 접합체 |
| JP7147270B2 (ja) | 2017-09-15 | 2022-10-05 | 日本電産株式会社 | 変速機及びアクチュエータ |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| FI3694529T3 (fi) | 2017-10-13 | 2024-09-17 | Harpoon Therapeutics Inc | Trispesifiset proteiinit ja niiden käyttömenetelmät |
| WO2019089848A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| WO2019136305A1 (en) | 2018-01-04 | 2019-07-11 | Neumedicines Inc. | Cell-based and immune checkpoint inhibitor therapies combined with il-12 for treating cancer |
| JP2021515806A (ja) | 2018-03-02 | 2021-06-24 | シーディアール−ライフ・アクチェンゲゼルシャフトＣｄｒ−Ｌｉｆｅ Ａｇ | 三重特異性抗原結合タンパク質 |
| MX2020012217A (es) | 2018-05-14 | 2021-03-02 | Harpoon Therapeutics Inc | Porción de unión para activación condicional de moléculas de inmunoglobulina. |
| US20210269530A1 (en) | 2018-05-14 | 2021-09-02 | Harpoon Therapeutics, Inc. | Conditionally activated binding protein comprising a sterically occluded target binding domain |
| WO2019222278A1 (en) | 2018-05-14 | 2019-11-21 | Harpoon Therapeutics, Inc. | Dual binding moiety |
| PE20210320A1 (es) | 2018-06-01 | 2021-02-16 | Novartis Ag | Moleculas de union contra bcma y usos de las mismas |
| WO2019246003A1 (en) | 2018-06-18 | 2019-12-26 | Anwita Biosciences, Inc. | Anti-mesothelin constructs and uses thereof |
| CN119751480A (zh) | 2018-09-11 | 2025-04-04 | Iteos比利时公司 | 作为a2a抑制剂的硫代氨基甲酸酯衍生物、其药物组合物以及与抗癌剂的组合 |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| US20210355219A1 (en) | 2018-09-21 | 2021-11-18 | Harpoon Therapeutics, Inc. | Conditionally activated target-binding molecules |
| WO2020060593A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Conditionally active receptors |
| CN113286817B (zh) | 2018-09-25 | 2025-01-28 | 哈普恩治疗公司 | Dll3结合蛋白及使用方法 |
| WO2020092792A2 (en) | 2018-10-31 | 2020-05-07 | Oncotracker, Inc. | Method of enhancing immune-based therapy |
| US12263190B2 (en) | 2018-11-08 | 2025-04-01 | Juno Therapeutics, Inc. | Methods and combinations for treatment and T cell modulation |
| CN109593786A (zh) | 2019-01-09 | 2019-04-09 | 上海怡豪生物科技有限公司 | 联合EpCAM和MSLN单链抗体的双靶点CAR载体及其构建方法和在乳腺癌应用 |
| EP3934761A1 (en) | 2019-03-05 | 2022-01-12 | Takeda Pharmaceutical Company Limited | Conditionally activated binding proteins containing fc regions and moieties targeting tumor antigens |
| AU2020275002A1 (en) | 2019-05-14 | 2021-12-23 | Harpoon Therapeutics, Inc. | EpCAM binding proteins and methods of use |
| CN114173815A (zh) | 2019-06-13 | 2022-03-11 | 西托姆克斯治疗公司 | 可活化抗pdl1抗体和抗ctla-4抗体在用于治疗癌症的联合疗法中的用途 |
| CN119679936A (zh) | 2019-06-24 | 2025-03-25 | 诺华股份有限公司 | 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法 |
| BR112021026376A2 (pt) | 2019-06-25 | 2022-05-10 | Gilead Sciences Inc | Proteínas de fusão flt3l-fc e métodos de uso |
| WO2021097060A1 (en) | 2019-11-13 | 2021-05-20 | Harpoon Therapeutics, Inc. | Pro immune modulating molecule comprising a clustering moiety |
| AU2021224851A1 (en) | 2020-02-21 | 2022-09-15 | Harpoon Therapeutics, Inc. | FLT3 binding proteins and methods of use |
| WO2021231434A1 (en) | 2020-05-12 | 2021-11-18 | Harpoon Therapeutics, Inc. | Psma targeting tritacs and methods of use |
| EP4192863A4 (en) | 2020-08-05 | 2025-07-30 | Synthekine Inc | IL2RG BINDING MOLECULES AND METHODS OF USE |
| US12234291B2 (en) | 2020-08-05 | 2025-02-25 | Synthekine, Inc. | IL2RB binding molecules and methods of use |
| US20240228656A1 (en) | 2020-11-06 | 2024-07-11 | Harpoon Therapeutics, Inc. | Epcam targeting trispecific protein for treatment of cancer |
| EP4304728A4 (en) | 2021-03-09 | 2025-08-20 | Harpoon Therapeutics Inc | COMBINATION THERAPY WITH IMMUNE CELL CONTACT PROTEINS AND IMMUNOMODULATORS |
| WO2022212732A1 (en) | 2021-04-01 | 2022-10-06 | Harpoon Therapeutics, Inc. | Psma targeting tritacs and methods of use |
| WO2022256498A1 (en) | 2021-06-03 | 2022-12-08 | Harpoon Therapeutics, Inc. | Msln targeting trispecific proteins and methods of use |
| AU2022286960A1 (en) | 2021-06-03 | 2024-01-18 | Harpoon Therapeutics, Inc. | Bcma targeting trispecific proteins and methods of use |
| AU2022286407A1 (en) | 2021-06-03 | 2024-01-04 | Harpoon Therapeutics, Inc. | Dll3 targeting trispecific proteins and methods of use |
| AU2022297538A1 (en) | 2021-06-25 | 2024-01-25 | Harpoon Therapeutics, Inc. | Extended-release immune cell engaging proteins and methods of treatment |
| WO2023064945A2 (en) | 2021-10-15 | 2023-04-20 | Harpoon Therapeutics, Inc. | Conditional activation of immunoglobulin molecules |
-
2016
- 2016-05-20 AU AU2016263808A patent/AU2016263808B2/en active Active
- 2016-05-20 IL IL274151A patent/IL274151B/en unknown
- 2016-05-20 IL IL293719A patent/IL293719B2/en unknown
- 2016-05-20 WO PCT/US2016/033644 patent/WO2016187594A1/en not_active Ceased
- 2016-05-20 KR KR1020197019089A patent/KR20190080992A/ko not_active Ceased
- 2016-05-20 CN CN202010099989.1A patent/CN111234027A/zh active Pending
- 2016-05-20 EA EA201792573A patent/EA201792573A1/ru unknown
- 2016-05-20 EP EP16797420.3A patent/EP3297672B1/en active Active
- 2016-05-20 KR KR1020177036948A patent/KR101997241B1/ko active Active
- 2016-05-20 EP EP21187762.6A patent/EP3932428A1/en not_active Withdrawn
- 2016-05-20 BR BR112017024899-9A patent/BR112017024899A2/pt not_active Application Discontinuation
- 2016-05-20 MX MX2017014908A patent/MX383614B/es unknown
- 2016-05-20 ES ES16797420T patent/ES2889906T3/es active Active
- 2016-05-20 US US15/160,984 patent/US9708412B2/en active Active
- 2016-05-20 JP JP2018512836A patent/JP6688551B2/ja active Active
- 2016-05-20 CN CN201680043021.9A patent/CN107849148B/zh active Active
- 2016-05-20 CA CA2986575A patent/CA2986575A1/en active Pending
- 2016-05-20 SG SG10202002131PA patent/SG10202002131PA/en unknown
-
2017
- 2017-06-22 US US15/630,259 patent/US10954311B2/en active Active
- 2017-11-20 IL IL255762A patent/IL255762B/en active IP Right Grant
- 2017-11-21 MX MX2021006615A patent/MX2021006615A/es unknown
-
2019
- 2019-04-03 AU AU2019202283A patent/AU2019202283B2/en active Active
-
2020
- 2020-04-02 JP JP2020066802A patent/JP6906653B2/ja active Active
-
2021
- 2021-02-02 US US17/165,760 patent/US12084518B2/en active Active
- 2021-02-16 AU AU2021201003A patent/AU2021201003B2/en active Active
- 2021-06-28 JP JP2021106877A patent/JP7411316B2/ja active Active
-
2024
- 2024-07-30 US US18/789,157 patent/US20250197526A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7411316B2 (ja) | 三重特異性結合タンパク質と使用方法 | |
| US20190225702A1 (en) | Innate immune cell trispecific binding proteins and methods of use | |
| JP7215997B2 (ja) | 前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法 | |
| HK40064939A (en) | Trispecific binding proteins and methods of use | |
| HK1252925B (en) | Trispecific binding proteins and methods of use | |
| EA042472B1 (ru) | Триспецифические связанные белки и способы их применения | |
| EA042513B1 (ru) | Psma-нацеленные триспецифические белки и способы их применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180119 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180418 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190516 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190517 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20190524 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20190606 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190701 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190924 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200309 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200403 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6688551 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |